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Abstract
Background: The aim of this study was to determine the effect of commonly self-prescribed
proton pump inhibitors (PPI) on the results of rapid urease test and histology for the diagnosis of
H. pylori infection.
Methods:  One hundred-nine consecutive patients with dyspeptic symptoms attending the
endoscopy suite were enrolled in this study. Antrum biopsy specimens were collected at
endoscopy for the rapid urease test (Pronto Dry, Medical Instrument Corp, France) and
histopathology. Sensitivity, specificity, positive predictive value (PPV), negative predictive value
(NPV) and like-hood ratio of a positive and negative of Pronto Dry test were compared against
histology. The gold standard test for the diagnosis of H. pylori infection was histopathology.
Results: Sixty-one percent (66/109) patients were males with mean age of 43 ± 14.1 years and age
range 17–80 years. Fifty-two percent (57/109) were not on any medications while 48% (52/109)
used PPI before presentation to the outpatients. Pronto Dry was positive in 40% (44/109) and
negative in 60% (65/109). Histopathology was positive for H. pylori in 57% (62/109) and negative in
43% (47/109). The sensitivity, specificity, PPV, NPV and like-hood ratio of a positive and negative
Pronto Dry test with and without PPI were 43.3%, 86.4%, 81.3%, 3.18, 0.656 and 52.8% vs 71.9%,
80%, 82.1%, 69%, 3.59 and 0.35.
Conclusion: This study shows that the sensitivity, specificity, NPV and PPV of rapid urease test
was reduced in patients who are on PPI. The exclusive use of the rapid urease test for the diagnosis
of Helicobacter pylori cannot be recommended in patients with prior PPI use.
Background
Helicobacter pylori (H. pylori) infection occurs worldwide.
It results in chronic gastritis, ulcer, mucosal associated
lymphomas and gastric carcinomas [1,2]. The diagnostic
methods available for detecting H. pylori infection include
serology (IgG ELISA), rapid urease test, histopathology,
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13 C-urea breath test (UBT) and polymerase chain reac-
tion (PCR) [3-5]. Rapid urease test is highly specific for H.
pylori infection and is commonly used for the detection of
H. pylori infection at endoscopy. It requires a high density
of bacteria, and anything that reduces the bacterial load
may produce false-negative tests. The diagnostic yield of
rapid urease test is enhanced by increasing the number of
biopsies taken and the number of sites in the stomach that
are biopsied [6]. The sensitivity of urease test is reduced in
patients who are taking proton pump inhibitors (PPI),
antibiotics or bismuth compounds [7,8]. Any antibiotic
active against H. pylori will cause a reduction in the num-
bers of bacteria in the stomach [9]. Also, if the patient has
received a drug that reduces the acid in the stomach and
raises the pH, this will affect the area of the stomach to be
biopsied [10]. H2-receptor antagonists (ranitidine and
cimetidine) raise the gastric pH, but PPI such as omepra-
zole and lansoprazole, raise the gastric pH to a higher
level. Proton pump inhibitors are known to decrease the
activity of H. pylori within the stomach and to shift their
distribution proximally [8]. H2-receptor antagonists differ
from proton pump inhibitors as high intragastric pH may
cause a reduction in urease activity, unrelated to a reduced
bacterial load [11]. This effect may reduce the sensitivity
of histological examination and rapid urease testing for H.
pylori on biopsies taken from recommended sites [8]. In
Pakistan a third world country self-prescription is com-
mon and medications are available on counter of pharma-
cies for sale without prescriptions [12,13]. Data from 66
pharmacies evaluated 1231 over-the-counter (OTC)
encounters, of which 43% were instances of self-medica-
tion, while the rest were given on the advice of pharmacy
staff [12]. Self-medication increased with the level of soci-
oeconomic status [13]. Proton pump inhibitors are much
cheaper than anti-H2 receptor blockers (H2-RB) costing as
much as 10 cents/pill. In a local tertiary care hospital the
prescriptions for PPI in 2003 alone numbered 31086 and
399189 tablets/injections were dispensed on prescrip-
tions. The aim of this study was to determine the effect of
commonly self-prescribed proton pump inhibitors (PPI)
on the results of the rapid urease test (Pronto Dry) and
histology.
Methods
One hundred-nine consecutive patients with dyspeptic
symptoms attending the endoscopy suite of gastroenterol-
ogy section of Aga Khan University Hospital, Karachi,
Pakistan from April 2004–January 2005 were enrolled.
There were sixty-six males and forty-three females (age
range 17–80 years, mean age 40.89 ± 12 years; Table 1).
Clinical symptoms at the time of presentation, diagnosis,
drug treatment dosage and duration were noted with
endoscopic findings. An informed consent was taken
from all patients and study was approved by the ethics
review committee. Four antral biopsy specimens were col-
lected at endoscopy from each patient two each for the
Pronto Dry (a commercially manufactured rapid urease
test by Medical Instrument Corp, France) and histopa-
thology. Pronto Dry consists of a dry filter paper contain-
ing urea, phenol red (a pH indicator), buffers and a
bacteriostatic agent in a sealed plastic slide. If the urease
enzyme of H. pylori is present in an inserted tissue sample,
the resulting decomposition of urea causes the pH to rise
and the color of the dot turns from yellow to a bright
magenta. Pronto Dry results were read in 30 minutes and
one hour after sampling as directed by the manufacturer.
The color change from yellow to pink was considered pos-
itive result and no color change as negative for Pronto
Dry. In this study sensitivity, specificity, positive predic-
tive value, negative predictive value and accuracy of
Pronto Dry were compared against histology in the pres-
ence and absence of PPI. Histopathologist was kept
blinded about the results of Pronto Dry. Two gastric antral
biopsy specimens for histopathology were stained with
Hematoxylin and eosin stain for the detection of H. pylori
Table 1: Clinical, endoscopic and histopathology findings of the 
patients (n = 109)
Factors With PPI n 
(%)
Without PPI n 
(%)
Gender
Male 35 (53) 31 (47)
Female 17 (40) 26 (60)
Age (in years) mean ± SD 42 ± 12.2 44 ± 15.6
Clinical feature
Abdominal pain 44 (54) 38 (46)
Heart burn 4 (57) 3 (43)
Vomiting 2 (29) 5 (71)
Dyspepsia 1 (11) 8 (89)
Weakness 1 (25) 3 (75)
Endoscopic findings
Gastritis 36(51) 35(49)
Gastritis and GERD 2(100) -
GERD 6(35) 11(65)
Gastric Ulcer - 3(100)
Duodenitis 7(64) 4(36)
Duodenal Ulcer 1(20) 4(80)
Urease Test
Positive 16 (36) 28 (64)
Negative 36 (55) 29 (45)
Histopathology
Positive 30 (48) 32 (52)
Negative 22 (47) 25 (53)
Results are presented as mean ± standard deviation and number 
(percentages).
SD = Standard DeviationBMC Gastroenterology 2005, 5:38 http://www.biomedcentral.com/1471-230X/5/38
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and degree of gastritis. In doubtful cases Giemsa staining
was carried out, to ascertain presence of H. pylori. The
degree of gastritis as determined on Hematoxylin and
eosin (H & E) stain was scored in accordance with the Syd-
ney system, representing absence of gastritis and minimal,
mild, moderate chronic active and severe chronic active
gastritis, respectively [14].
Statistical Analysis
Data was entered and analyzed in Statistical Package for
Social Sciences (SPSS) ver13.0. Results are presented as
mean ± standard deviation for quantitative variables and
number (percentages) for qualitative variables. Sensitiv-
ity, specificity, positive and negative predictive values of
urease test was calculated by two by two standard method.
Likelihood ratio of a positive test was equal to sensitivity/
(1-specificity) and of a negative test was (1 - sensitivity)/
specificity.
Results
There were 57% (66/109) males and 43% (43/109)
females with age range 17–80 years and mean age of 43 ±
14.1 years (Table 1). 52% (57/109) were not on any med-
ications while 48% (52/109) used PPI before presentation
to the outpatients.
Clinical Features
Abdominal pain was present in 75% (82/109), dyspepsia
8% (9/109), vomiting 6% (7/109), heartburn in 6% (7/
109), and weakness 5% (4/109) (Table 1). The main
endoscopic findings were gastritis 65% (71/109), gastro-
esophageal reflux disease 16% (17/109) and duodenitis
in 10% (11/109) (Table 1).
Urease test
Pronto Dry was positive in 40% (44/109) and negative in
60% (65/109) (Table 1). The sensitivity, specificity, NPV
and PPV of Pronto Dry with and without PPI was 43.3%,
86.4%, 81.3% and 52.8% vs. 71.9%, 80%, 82.1% and
69% (Table 2).
Histopathology
Histopathology was positive for H. pylori in 57% (62/
109) and negative in 43% (47/109) (Table 1).
Comparison of Urease test and Histopathology
The sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) of urease test was
reduced on PPI (Table 2). The likelihood of a positive ure-
ase test with and without PPI was 3.18 and 3.59 and neg-
ative urease test with and without PPI was 0.65 and 0.35.
Discussion
The rapid urease test is the most frequently used test for
the diagnosis of H. pylori infection in routine gastrointes-
tinal endoscopy practice. It is extremely valuable because
it gives a positive result for H. pylori infection before the
patient leaves the endoscopic suite. Histological diagnosis
of H. pylori infection is usually reserved for patients with a
negative biopsy urease test or when histology was
required for another reason such as exclusion of malig-
nancy. In an earlier study rapid urease test (Pronto Dry)
had the sensitivity, specificity, positive predictive value,
negative predictive value and diagnostic accuracy were
98%, 100%, 100%, 98% and 99%, respectively [15]. The
sensitivity and specificity of Pronto Dry against culture
were 98% and 97% [16].
In this study treatment with a PPI before endoscopy
reduced the sensitivity of urease test from antral biopsies
for H. pylori detection. Ideally PPI should be discontinued
before the endoscopy [8]. However, in our practice
patients quite frequently self medicate. Even referrals from
primary care service cannot be discontinuing PPIs for an
adequate period before endoscopy. In patients on PPI the
biopsy specimen may contain low bacterial density of via-
ble cells giving a negative urease test. This also leads to
lack of H. pylori identification on histology. Of the various
tests that are available for H. pylori detection, histological
examination of gastric biopsy is considered the most accu-
rate method of diagnosis [6]. In a previous study even his-
tological examination sensitivity, specificity, positive
predictive value, negative predictive value and diagnostic
accuracy were demonstrated to be reduced on acid reduc-
ing drugs [8]. It was demonstrated that after 4 weeks of
omeprazole treatment, the histological density of H. pylori
in the antrum and corpus was reduced, while that in the
fundus was increased [17]. The migration of H. pylori from
the antrum to the fundus was also associated with a corre-
sponding decrease in the activity of antral gastritis and
Table 2: The comparison of Urease test and histopathology with the presence and absence of PPI.
Test Sensitivity (95% C.I.) Specificity (95% C.I.) PPV (95% C.I.) NPV (95% C.I.)
Urease Test with PPI 43.3% (30.9–50.6%) 86.4% (69.5–96.2%) 81.3% (58–94.8%) 52.8% (42.4–58.3%)
Urease Test without PPI 71.9% (59.2–80.7%) 80% (63.7–91.3%) 82.1% (67.6–92.3%) 69% (55–78.7%)
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matched by a progressive fall in the excretion of 13C urea
breath test [17]. In an animal model of H. pylori infection
antrum-body transitional zone was identified as a sanctu-
ary site in treatment failure [18]. If more than one gastric
biopsy tissue is used to inoculate the rapid urease test a
positive test might appear thus improving the test sensitiv-
ity without compromising its specificity. The diagnostic
yield is said to be increased by over 5% by taking more
than a single biopsy [6]. However, this also prolongs the
endoscopy time. Our study showed the likelihood of a
negative urease test with and without PPI was 0.65 and
0.35, respectively. Hence, in patients on PPI additional
biopsies should be taken from the body of the stomach
beside the antrum for the detection of H. pylori. This will
be consistent with previous studies which recommend
obtaining biopsies both from antrum and body of the
stomach in patients on PPIs for the diagnosis of H. pylori
infection [6,8]. This is also important in view of the high
prevalence of H. pylori in the region. As rapid urease test
can miss a low-level infection with H. pylori, a negative test
should not be the sole criterion for either absence or cure
of H. pylori infection. A negative diagnosis on PPI might
be backed up with a serological test which should not be
affected by PPI. Also, in view of the small sample size of
our study, the result needs to be confirmed in a larger pop-
ulation of patients. In conclusion it is of particular rele-
vance to know if a PPI has been used before the patient
undergoes diagnostic endoscopy. If PPI can not be discon-
tinued for an adequate period before the endoscopy mul-
tiple biopsies should be taken from both the antrum and
the body of the stomach for H. pylori detection.
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